 Shares of Epizyme Inc. were up 11.0 in premarket trading on Friday after SVB Leerink upgraded the companys stock to outperform, from market perform, citing Tazveriks potential opportunity in the follicular lymphoma market. Analyst Andrew Berens told investors that the drugs potential as a maintenance therapy could represent a significant upside to current valuation. 